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Abstract  
Titin truncating variants (TTNtv) commonly cause dilated cardiomyopathy (DCM). However, TTNtv are 
also encountered in ~1% of the general population but potentially silent, perhaps reflecting position-
dependent allelic factors. To better understand TTNtv we integrated TTN allelic series, cardiac 
imaging and genomic data from human cohorts and studied rat models with disparate TTNtv. In 
patients with DCM, TTNtv throughout the TTN molecule were significantly associated with DCM, 
although more strongly so (odds ratio ~50) when located in the A-band. Ribosomal profiling in rat 
revealed the translational footprint of premature stop codons in Ttn and showed TTNtv position-
independent nonsense-mediated degradation of the mutant allele and a signature of perturbed 
cardiac metabolism. Heart physiology in TTNtv rats was unremarkable at baseline but became 
impaired during cardiac stress. In healthy humans, TTNtv were associated with eccentric cardiac 
remodelling, which is a feature of DCM. These data show that TTNtv have molecular and 
physiological effects on the heart across species, with a continuum of expressivity in health and 
disease. 
 
 
  
 Dilated cardiomyopathy (DCM) has a prevalence of up to 1:2501, is the commonest indication for 
heart transplantation and is often associated with titin truncating variants (TTNtv, 15-20% of DCM 
cases), which are enriched in the TTN A-band2,3. A surprising ~1% of the general population has a 
TTNtv in the absence of DCM, which has stimulated much debate as to the pathogenicity of TTNtv4–7. 
It has been suggested that TTNtv in the healthy population may be phenotypically silent and that 
TTNtv that segregate in familial DCM are perhaps modifiers of other DCM-causing variants3. 
However, it is also known that genetic variation affecting disease genes can be associated with 
quantitative variation in the physiology of healthy individuals8, which has not been assessed formally 
for TTNtv. 
 
We showed previously that TTN exon characteristics are important determinants of TTNtv 
pathogenicity. Variants encoded in exons that are not spliced into TTN isoforms expressed in the 
heart (non-cardiac exons with ‘Percent Spliced In’ (PSI) < 15%) are not associated with DCM3, while 
variants encoded in exons that only incorporate into the N2BA and not into the N2B isoform have 
weak associations with disease. In studies of human induced pluripotent stem cell (iPSC)-derived 
cardiomyocytes (iPSC-CMs)9 alternative exon splicing is a major mechanism for reduced penetrance 
for some I-band TTNtv. When taking only TTNtv that are located in cardiac exons (PSI > 15%) into 
account, approximately 0.5% of the general population have a TTNtv that might be expected to cause 
DCM but does not.  
 
In addition to the complexities surrounding TTNtv penetrance, the molecular mechanisms underlying 
TTNtv are uncharacterized. Nonsense-mediated decay (NMD) of the mutated allele by RNA-seq or a 
reduction in full-length TTN by agarose gel analysis has not been demonstrated, which if documented 
would support a haploinsufficient disease mechanism3,9,10. Equally, accumulation of a truncated TTN 
protein molecule is not apparent in human heart samples 3 and is rarely present in iPSC-CMs9 
suggesting a poison-peptide/dominant negative mechanism to be unlikely.  
 
Here, we undertook studies of DCM patients, rat models of TTNtv and human volunteers from the 
general population to better understand TTNtv pathogenicity and molecular effect with a specific focus 
on dissecting a hypothesized position-dependent penetrance effect of TTNtv alleles. To do this, we 
performed a meta-analysis of TTNtv in DCM patients (n = 2,495) as compared to controls (n = 
61,834) and generated two rat models of TTNtv with mutations at opposite ends of the Ttn molecule. 
We integrated RNA-sequencing (RNA-seq) and ribosome profiling (Ribo-seq) data across models and 
species and performed metabolic and signaling studies to outline potential disease mechanisms. To 
define the effects of TTNtv on the heart in the general population we combined 2D and 3D cardiac 
magnetic resonance imaging (CMR) with TTN sequencing in healthy volunteers (n = 1,409).  
 
 
 
Results 
TTNtv in constitutive exons across the TTN molecule from the Z-disc to the M-band are 
associated with DCM  
We and others have shown that A-band TTNtv are associated with DCM2,3,9 but the association of 
DCM with TTNtv in the I-band, Z-disc or the M-line has not been demonstrated and it is suggested 
that proximal TTNtv, in particular, may be non-penetrant. To address variant effect across the TTN 
molecule we retrieved TTNtv alleles from DCM patients from available sources, combined these data 
with novel DCM cases (n = 1,105) and performed a meta-analysis using ExAC11 and other controls 
(cohort totals: DCM (n = 2,495) controls (n = 61,834); see Methods). This showed that TTNtv in 
constitutive exons (PSI > 90%) are significantly associated with DCM irrespective of their position in 
TTN (Table 1).  
While some I-band TTNtv may be rescued by differential splicing9, we observed that I-band TTNtv in 
constitutive cardiac exons were significantly associated with DCM, which was true for both proximal 
and distal I-band variants. TTNtv in Z-disc exons were also associated with DCM, although with a 
much lower odds ratio (OR: 5.3) than A-band TTNtv (OR: 49.8). It has been proposed that a distal 
internal promoter of the Cronos TTN isoform12, which we confirmed to be present in adult human 
heart using Cap Analysis of Gene Expression (CAGE)13 data (Fig S1), can rescue proximal TTNtv 
effect. However, we found that proximal TTNtv are also penetrant and associated with DCM. By 
splitting regions of titin into protein regions (Table 1), or consecutive uniformly-sized bins (n = 40, (Fig 
S2)) we were able to show the proportion of truncations that are penetrant (etiological fraction) in 
regions of TTN upstream of the Cronos promoter is comparable to the proportion in the downstream 
A-Band. These data show that distal I-band and all A-band TTNtv have larger ORs than very proximal 
or distal variants, which suggests position-dependent effects for the penetrance of TTNtv in DCM. 
 
Table 1. Meta-analysis shows an association of TTNtv in constitutive exons throughout the gene with DCM. Exon 
usage are displayed base on the levels of PSI14. Constitutive exons are spliced into titin isoforms with an efficiency of at least 
90%. OR, odds ratio. EF, etiologic fraction. P-values indicate significant enrichment for TTNtv in DCM (binomial test). 
   
DCM 
Positive 
Control 
Positive 
DCM 
Prevalence 
(%)  
Control 
Prevalence 
(%) 
OR OR 
(hi) 
OR 
(lo) 
EF P-value  
   (n=2,495)  (n=61,834) 
Sarcomere domain 
affected by variant 
         
A-band (constitutive) 268 149 10.74 0.24 49.8 61.1 40.6 0.98 2.4x10-260 
I-band (Distal constitutive 
Post-Cronos) 
9 7 0.36 0.01 32.0 85.9 11.9 0.97 2.5x10-9 
I-band (Distal constitutive 
Pre-Cronos) 
18 23 0.72 0.04 19.5 36.2 10.5 0.95 6.6x10-15 
I-band (Non-constitutive) 6 102 0.24 0.17 1.5 3.3 0.6 0.31 0.46 
I-band  
(Proximal constitutive) 
22 29 0.88 0.05 19.0 33.0 10.9 0.95 1.1x10-17 
M-band (constitutive) 6 40 0.24 0.07 3.7 8.8 1.6 0.73 0.01 
Z-disc (constitutive) 7 33 0.28 0.05 5.3 11.9 2.3 0.81 0.001 
Z-disc (Non-constitutive) 0 11 0.00 0.02 NA NA NA NA NA 
Premature stop codons cause nonsense-mediated RNA decay and disrupt translation of full 
length, sarcomere-spanning Ttn 
Our meta-analyses of DCM patients showed that TTNtv throughout the TTN molecule are penetrant 
but have variable, position-related odds ratios. To study putative position-dependent effects in greater 
detail while controlling for other genetic and non-genetic factors we modelled proximal and distal 
TTNtv in two independent rat strains on the same genetic background (TTNtvA: with variation in the 
A-band; TTNtvZ: with variation in the Z-disc; for details see Fig S3). Animals with homozygous 
mutations were not viable, as previously described for TTNtv in the mouse10 while heterozygous 
animals were born in normal Mendelian ratios (data not shown).  
 
We bred TTNtv heterozygous rats on a F344 background with Ttn wild type Brown Norway rats to 
obtain an F1 cross to specifically enable allele-specific analysis of Ttn transcription and translation in 
the heart using RNA-seq and Ribo-seq (Fig 1a and Fig S4)15,16. Ribosome protected fragments 
(RPFs) showed clear trinucleotide periodicity across the translatome, indicating actively translating 
ribosomes (Fig 1b). Ttn transcripts with a truncation in the A-band were transcribed and translated as 
far as the premature nonsense codon, which efficiently stopped translation thereafter (Fig 1c,d). 
 
  
 Fig 1. Ribosome profiling reveals the translational footprint of truncating variants in Ttn. a Ribosome occupancy across 
Ttn: Average reads per kilobase per million mapped reads (RPKM) per exon for 10 BN/F344 F1 rats. F344 SNPs on the BN 
background (n=121) allow assessment of allele-specific translation for 2 distinct models of truncations and Ttn wild type animals. 
Proximal and distal truncations affect different isoform populations of Ttn. Purple indicates Z-disc, green I-band, pink A-band and 
blue M-line. b Ribo-seq reads (28-mers) show clear 3-nt periodicity across the genome for all replicates indicating that the 
datasets effectively capture actively translating ribosomes in the heart at a high resolution. c,d Ribosomes occupy the F344 allele 
in TTNtvA animals upstream of the premature stop codon in the A-band of Ttn exposing the synthesis of truncated Ttn isoforms. 
The premature stop efficiently releases ribosomes from the mutant Ttn message. Ttn protein synthesized after TTNtvA is 
exclusively generated from the healthy BN allele (Whiskers show 10-90 percentile). Allele frequencies in both RNA-seq and Ribo-
seq were consistently below 50%, indicative for NMD. e F344 SNPs located after TTNtvZ are occupied by ribosomes, indicating 
translation after the proximal truncation in Ttn. f Ribo-seq reads located downstream of TTNtvZ do not lower 3-nt periodicity 
across exons suggesting that they actively translate canonical Ttn sequence at similar levels as animals with two wild type Ttn 
alleles. g TTNtvZ reduces ribosome density initially but translation of Ttn is gradually rescued after the frameshift in the Z-disc. 
Translation of A-band exons, but not of I-band exons, is reduced in mutants compared to WT animals. TTNtvA efficiently reduces 
translation after the premature stop codon. 
 
The premature stop codon of the TTNtvZ allele did not prevent translation downstream of the non-
canonical stop and F344 SNPs encoded on the truncated Ttn allele were detected throughout Ttn 
(Fig. 1e). Rescue of translation from the truncated F344 allele did not decrease the 3-nt periodicity 
across Ttn when compared to F1 wild type (WT) animals that synthesize Ttn from two healthy alleles 
(Fig. 1f). Exon-level analyses showed that the TTNtvZ variant initially reduces ribosome occupancy at 
the N-terminus of Ttn (~50% that of WT) but subsequently translation is partially recovered (Fig 1g). 
This apparent rescue of translation might be explained in parts by internal ribosomal entry sites, 
transcription start sites that generate Ttn isoforms with alternative N-termini and potentially by factors 
that maintain ribosomes on the huge Ttn molecule during its translation. In support of this, human 
CAGE data13 and epigenetic marks17 revealed distal TTN promoters in the human heart (Fig S1), as 
previously suggested12. In TTNtvA animals, we only detected ribosomes on the healthy BN allele after 
the premature stop codon (Fig 1c). This led to a decrease of ribosome occupancy by 50% when we 
compared to WT animals that still translate this section of titin from both alleles (Fig 1g). 
 
In both mutant rats there was a relative increase in exon translation in the I-band (Fig. 1g) that reflects 
differential Ttn mRNA processing and higher PSI ratios14 of exons in the I-band, as observed in 
human iPS-derived cardiomyocytes with TTNtv9. This is indicative of an increase in N2BA isoform 
expression in TTNtv carriers. To translate this finding, we compared cardiac RNA-seq data3 from 
DCM patients either with (n = 17) or without (n = 91) a TTNtv and observed similar patterns of 
alternative splicing as seen in the rat models (Fig 2a). Allele-specific RNA-seq data revealed a slight 
upregulation of the WT allele and profound NMD of the allele carrying the TTNtv in both the TTNtvA 
and the TTNtvZ models (Fig 2b). These data demonstrate a multi-allelic effect of TTNtv on the overall 
TTN isoform composition across species (that can cause DCM18,19), and that TTNtv confer position-
independent NMD.  
 
 Fig 2. Proximal and distal truncations in titin alter isoform processing and trigger NMD. a PSI and deltaPSI of titin exons 
expressed in the heart for TTNtvA, TTNtvZ and WT animals and human DCM. Exons with at least 10 inclusion reads are marked 
in solid colours. Truncating mutations in titin activate splicing in of I-band exons in the TTNtv rat models and also human DCM 
patients that carry TTN truncations. b RNA-seq reads assigned to either BN or F344 alleles: TTNtv selectively trigger nonsense-
mediated decay of truncated Ttn transcripts. c Ribo-seq expression of exons that are exclusively being synthesized in TTNtvA 
and TTNtvZ animals reveal that both TTNtv models generate 60% of full-length titin compared to WT. Purple indicates Z-disc, 
green I-band, pink A-band and blue M-line. *P < 0.05; **P < 0.01. 
 
It was noticeable that both the proximal and the distal TTNtv triggered NMD with identical efficiencies 
irrespective of their location in the Ttn molecule. The fact that the proximal truncation triggers NMD 
indicates that the premature stop codon close to the N-terminus in the TTNtvZ is functional and that 
ribosomes cannot clear exon-exon junction complexes20,21. Assessing translation beyond the 
truncation in the TTNtvA model and within the 4-exon deletion in TTNtvZ revealed that both rat 
models synthesize lesser amounts (~60% of WT rats) of full-length, sarcomere-spanning Ttn (Fig 2c). 
In keeping with our published data3, protein gel electrophoresis did not identify a truncated Ttn 
isoform or a reduction in the Ttn:Mhc ratio in mutant rat heart (Fig S5). This suggests rapid turnover of 
mutant protein that, for the first time, we document the existence of by showing its synthesis (Fig 1). It 
also shows that while there are significantly less ribosomes translating full length protein, TTN protein 
changes are not apparent at the resolution of gel analysis. Overall changes in full length TTN protein 
might be compensated not just by an upregulation of the wildtype allele (P = 0.02; Fig 2b), but also via 
an increase in ribosome translational speed or changes in protein-turnover. 
 
Taken together these data show that proximal and distal Ttn truncations disrupt Ttn protein synthesis 
but have different translational footprints. However, their effect on NMD of the sarcomere-spanning 
Ttn isoforms is similar and leads to identical reductions in full-length Ttn expression. 
 
Titin truncations cause position-independent perturbation of cardiac metabolism and 
signaling  
To determine whether distinct or similar molecular phenotypes are associated with proximal or distal 
TTNtv, we performed pathway analysis22 of the genome-wide transcription (RNA-seq) and translation 
(Ribo-seq) profiles of TTNtvZ and TTNtvA as compared to controls. The gene expression differences 
observed between TTNtv animals and WT controls were highly correlated for TTNtvA and TTNtvZ 
both for RNA-seq and also Ribo-seq data, showing both mutant strains to have similarly perturbed 
transcriptomes (R2 = 0.841; P < 0.0001) and translatomes (R2 = 0.837; P < 0.0001; see also Fig S6 & 
Table S1). Gene set enrichment analyses showed significantly overlapping KEGG22,23 terms between 
TTNtv animals when compared to WT (RNA-seq P value < 10-15; Ribo-seq P value < 10-15; Pearson 
Chi-square test; Fig 3a), which suggested altered cardiac metabolism that was independent of the 
position of the TTNtv. 
 
To investigate further the molecular signatures of altered cardiac metabolism in mutant animals, we 
performed quantitative metabolomic profiling of WT and TTNtv hearts. Liquid chromatography mass 
spectrometry (LC-MS) showed reduced amounts of medium and long chain fatty acid acyl-carnitines 
in TTNtv hearts as compared to controls (Fig 3b; Table S2). We also performed capillary 
electrophoresis mass spectrometry, complementary to LC-MS, and observed accumulation of 
alternative myocardial substrates (branched-chain amino acid metabolites and glycolytic 
intermediates; Fig 3c-e; Fig S7) in mutants. These changes are similar to those seen in the failing 
heart and the pressure-loaded non-failing heart24,25 and are associated with a shift in cardiac 
metabolism away from fatty acids and towards glycolysis, which may be adaptive26–28. There was no 
change in the major energy substrates (e.g. ATP; Fig S8), which are only diminished in advanced 
cardiac failure29.  
 
The signaling changes in the heart due to TTNtv are likely many. We found that variation in metabolic 
proteins interacting with TTN, such as FHL2 (Fig S9), are small and their functional role cannot be 
established based on these data alone. It is known that mTORC1 signaling is activated in familial 
DCM30 and its activity is detrimental in a mouse model of DCM due to LMNA mutation31. We profiled 
the mTORC1 pathway in the TTNtv rat hearts, where metabolites that activate mTOR32 are elevated 
(Fig 3) and observed activation of this pathway (Fig S10). The relative importance of these signaling 
variations for DCM pathobiology remain to be established. 
 Fig 3. Hearts with proximal and distal truncations in titin undergo metabolic reprogramming. a Pathway analyses based 
on RNA-seq and Ribo-seq data suggest perturbed metabolism, structural integrity and mechano-sensation of the TTNtv heart. 
This molecular signature is strikingly similar in rats with proximal and distal truncations (P value < 10-15; Pearson Chi-square test). 
b Unsupervised clustering by k-means of cardiac fatty acid acylcarnitine abundance in WT (n=5) and TTNtv (n=10) rats. –OH 
and –DC designate hydroxylated and dicarboxylic acid acylcarnitine species respectively. Metabolite profiles showing c branched 
chain amino acids (valine, leucine and isoleucine), d sum of measured glycolytic intermediates (metabolites are detailed in Table 
S3) and e glucose-6-phosphate (G6P) in cardiac tissue of WT (n=6) and TTNtv (n=12) rats. For individual genotypes (WT vs 
TTNtvA or TTNtvZ) see Fig S7. *P < 0.05; **P < 0.01; ***P < 0.001. 
 
TTNtv impair cardiac performance during stress in rats and have adversely effect the heart in 
the general population 
In young TTNtv rats (<8 months old) cardiac imaging showed features of concentric remodeling but 
normal LV mass and systolic function (Fig S11). In older rats (>1 year), TTNtv hearts were similar to 
controls although with a suggestion of slightly impaired systolic function (Fig 4a, Fig S12). While 
changes in cardiac morphology and function were mild in young mutant rats it was possible that this 
represented a compensated state as evidenced by the shift in cardiac metabolism (Fig 3) that is 
adaptive, at least in the short term26. We examined cardiac function ex vivo and used a volume 
overload model to test the Frank-Starling response, which may be specifically impaired by genetic 
variation in TTN33. Under basal conditions (LV end diastolic pressure, 5-10mmHg) TTNtv rat hearts 
tended to have higher strain rates and LV developed pressures, perhaps reflecting compensatory 
metabolism (Fig 3) and signalling (Fig S10) but, when subjected to sequential volume overload stress, 
mutant heart function became increasingly impaired (Fig 4b). As observed previously34–36, cardiac 
stress ex vivo activated mTORC1 signaling in control animals, which is an adaptive response. 
However, TTNtv hearts had elevated mTORC1 signaling at baseline and were not able to 
appropriately increase mTORC1 activity further when stressed (see Fig S10).  
 
In the rat, TTNtv had mild effects on heart function irrespective of their position in the Ttn molecule but 
did not cause DCM. To explore the possibility that TTNtv in cardiac exons similarly affect the heart in 
human subjects, irrespective of disease status, we recruited 1,409 healthy individuals for detailed 
CMR studies of the heart in combination with TTN sequencing. We specifically focused our studies on 
the cardiac parameters of LV end diastolic volume (LVEDV) and ejection fraction (EF) that are used to 
define DCM37 and also LV end systolic volume (LVESV) that is elevated in pre-DCM and predicts 
heart failure onset38. In this cohort we identified 15 TTNtv (see Table S4; prevalence = 1.0%) in TTN 
exons (PSI > 15%), in keeping with our previous findings3 and the data from the ExAC Consortium11. 
Truncations in TTN in our cohort and in the ExAC dataset were equally distributed across the TTN 
molecule (Fig S13). 
 
 Fig 4. TTNtv in rats and humans adversely affect cardiac geometry and function. a SV (Stroke Volume), LVEF (Left 
Ventricular Ejection Fraction) and FWT (Fractional Wall Thickening) measured with CMR in 13-16 month old male WT (n=5) and 
TTNtv (TTNtvA, n=8; TTNtvZ, n=6) rats. Data are mean ± SD; [Statistical analysis by Student’s t test]. For individual genotypes 
(WT vs TTNtvA or TTNtvZ) see Fig S12. b Measurements of ex vivo myocardial function during volume overload stress in 4 
month old WT (n=9) and TTNtv (TTNtvA, n=8; TTNtvZ, n=8) rats. TTNtv hearts have mildly increased dp/dt max/min and LVDevP 
at baseline. Myocardial contraction rate, dp/dt max (mmHg/s); myocardial relaxation rate, dp/dt min (-mmHg/s); Left ventricle 
developed pressure, LVDevP (mmHg). Data are mean ± SEM; P values indicate statistical analysis by two-way analysis of 
variance [ANOVA]. c and d, human data. c Univariate analyses of left ventricular end diastolic volume (LVEDV), LEVEDV indexed 
to body surface area (LVEDVI), left ventricular end systolic volume (LVESV) and LVESV indexed to body surface area (LVESVI). 
Healthy human individuals without a TTNtv in a cardiac exon (TTNtv-) are compared to healthy humans with a TTNtv (TTNtv+). 
Data are mean ± SD. [Mann-Whitney] d Computational modeling of cardiac geometry in healthy humans using 3D CMR. Positive 
standardised beta coefficients indicate where TTNtv genotype status (cardiac exons with PSI > 15%) is associated with 
enlargement of the LV cavity at end-diastole and end-systole. Septal and lateral en face projections are shown with an outline of 
the LV myocardium. The area enclosed by the yellow contour has a corrected P <0.05 [mass univariate linear regression]. e The 
distribution of corrected P values (< 0.05 threshold shown) as a proportion of the endocardial surface is shown for both diastole 
(left panel) and systole (right panel) [mass univariate linear regression].  
 
After genotype-blinded analysis of CMR data, we found that no individual from the general population 
with a TTNtv had imaging criteria for DCM, similar to our observations in the rat models and previous 
studies3. However, in univariate analyses TTNtv conferred a significant increase in absolute LV 
volumes and had more pronounced effects on volumes indexed to body surface area (Fig 4c). There 
was a non-significant trend for a lower LVEF in TTNtv+ individuals (LVEF (%): TTNtv+, 66 ± 5; TTNtv-
, 63 ± 5; P = 0.06, Mann-Whitney). Given the multiple clinical and anthropometric variables that 
predict cardiac morphology and function, we built regression models for LVEDV, LVESV and LVEF 
(see Methods and Table S5) and tested whether addition of TTNtv status improved model 
performance, which turned out to be the case (absolute beta values: LVEDV, +11.8mls (8.1%); 
LVESV +7.7 mls (15%); EF = -2.8% (P<0.03 for all)). Of note, the effect size of TTNtv on cardiac 
parameters was much greater than the effect sizes of cardiovascular GWAS loci (e.g. systolic blood 
pressure; combined effect of all GWAS loci ~3%)39,40. 
To complement our 2D studies we collected an independent dataset of 3D CMR images and, blinded 
to genotype, performed atlas- and machine-based analyses of LV geometry with respect to TTNtv 
status41,42. The 3D data show that TTNtv were associated with eccentric cardiac remodeling in healthy 
individuals.  This was defined by outwards displacement of the endocardial border of the heart (Fig 
4d,e and Supplementary video 1) in both systole (79% of total surface, P < 0.05) and diastole (47% of 
total surface, P < 0.05), in consensus with the 2D data.  
 
Discussion 
Here we studied the effects of TTNtv in patients with DCM, in the rat and in healthy humans to better 
understand these variants that represent the commonest genetic cause of DCM, yet are prevalent in 
the general population. At the molecular level, we found that TTNtv cause altered I-band splicing and 
position-independent NMD, which attenuates the synthesis of sarcomere-spanning Ttn isoforms. The 
NMD of the TTNtv allele that we observed in the F1 rat cross is the first demonstration of this effect 
and something we were not able to show previously using unphased human RNA-seq3. Distal 
truncations are associated with synthesis of carboxy-terminus truncated Ttn isoforms, whereas 
proximal TTNtv lead to translation of additional Ttn isoforms with alternative amino-termini. None of 
these additional isoforms were detected on protein gels, which suggests rapid degradation of these 
species (Fig S5). It was notable that, irrespective of their position in the Ttn molecule, both proximal 
and distal premature stop codons in the rat caused highly similar gene expression and translational 
signatures. While these molecular phenotypes are sufficient to impact heart function, it does not 
exclude additional, position-dependent effects that modify TTNtv penetrance in DCM where distal I-
band and all A-band TTNtvs have the highest ORs. 
 
The molecular phenotype due to TTNtv, which is reminiscent of cardiac adaptation to heart failure 
stimuli with a shift away from fatty acid metabolism26–28, was associated with activation of the 
mTORC1 pathway that is also activated in familial DCM30.  We suggest that the metabolic (Fig 3) and 
signalling (Fig S10) changes in the TTNtv heart represent adaptive mechanisms26–28 and that the 
heart is maintained in a compensated state and therefore inflexible to further stress. This may explain 
why hemodynamic stress associated with pregnancy or possibly a second genetic factor may reveal 
TTNtv effects43.  
 
We found that TTNtv in constitutive exons throughout the TTN molecule, from the Z-disc to the M-line, 
are significantly associated with DCM. This has implications for interpretation of TTNtv in patients with 
DCM although A-band and distal I-band TTNtv have higher ORs than variants in other TTN domains, 
for reasons that remain unclear. In the general population, we show that TTNtv that were previously 
thought to be of limited consequence44 are associated with higher left ventricular volumes in 2D CMR 
analyses, which reflects underlying eccentric remodelling that was revealed using advanced 3D CMR 
techniques. The magnitude of effect of TTNtv on cardiac geometry in the general population may be 
large enough to adversely influence future cardiac events, which requires further study.  
 
We note that TTNtv in exons that are expressed in the heart (PSI > 15%) are present in about 0.5% of 
individuals across all ethnicities3,11 and it may be that this variant class is of clinical relevance to ~35 
million people, particularly if they are exposed to additional genetic or environmental cardiac stresses. 
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